Complement activation contributes to platelet destruction in immune thrombocytopenia (ITP). However, there has been very little data describing serum complement levels in ITP patients, and no data ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...
The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results